Table 2.
Cell line | Drugs | IC50 (μM) determined at different times | ||
---|---|---|---|---|
24 h | 48 h | 72 h | ||
Bcap‐37 | Cisplatin | 20.5 ± 0.8 | 2.3 ± 0.6 | 1.9 ± 0.4 |
Carboplatin | 265.0 ± 5.2** | 152.9 ± 12.1** | 78.8 ± 16.3** | |
Oxaliplatin | 100.8 ± 13.0** | 38.6 ± 1.6** | 13.5 ± 1.2* | |
γ‐PGA‐CDDP | 102.6 ± 6.1** | 25.2 ± 2.6** | 5.5 ± 0.6 | |
BEL‐7404 | Cisplatin | 62.0 ± 11.4 | 11.1 ± 0.6 | 9.5 ± 0.5 |
Carboplatin | 505.6 ± 108.3** | 190.8 ± 17.8** | 180.2 ± 18.2** | |
Oxaliplatin | 92.2 ± 15.9 | 24.7 ± 3.3 | 22.4 ± 2.0 | |
γ‐PGA‐CDDP | 149.9 ± 12.5 | 44.2 ± 6.8** | 30.0 ± 3.4* | |
SH‐SY5Y | Cisplatin | 62.3 ± 13.1 | 28.6 ± 4.1 | 4.2 ± 0.5 |
Carboplatin | 308.9 ± 63.0** | 150.0 ± 43.5** | 37.52 ± 7.6** | |
Oxaliplatin | 138.1 ± 12.4* | 59.8 ± 7.8 | 2.8 ± 0.6 | |
γ‐PGA‐CDDP | 217.6 ± 42.0** | 86.0 ± 10.0* | 17.6 ± 1.2** |
Fifty percent inhibitory concentration was evaluated by MTT assay. Each value was the mean of four data points. *P < 0.05 drugs vs CDDP. **P < 0.01 drugs vs CDDP.